A Phase 3 interventional study of HS-10506 and Placebo in Insomnia Disorder, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.
The study will comprise 4 periods : a Screening Period, a Run-in Period, a Treatment Period during which participants will be treated for 84 nights (3 month) and a minimum 3-day Follow-up Period before an End of Study (EOS) Visit. The total study duration for each participant on this study is 105-113 days.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.
This study's planned enrollment of 732 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive HS-10506 tablets, orally, once nightly for 84 consecutive nights
Drug: HS-10506
Participants will receive placebo matched in appearance to HS-10506 tablets, orally, once nightly for 84 consecutive nights
Drug: Placebo
HS-10506 tablet
Placebo tablet matched to HS-10506
Change from baseline of mean latency to persistent sleep (LPS) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
LPS was defined as the time in minutes from lights off to the first epoch of 20 consecutive epochs of non-wakefulness as measured by polysomnography (PSG)
Time frame: Baseline, Night 27 and Night 28,Night 83 and Night 84
Change from baseline of mean wakefulness after sleep onset (WASO) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
WASO was defined as minutes of wake from the onset of persistent sleep until lights on as measured by PSG
Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84
Change from baseline of subjective sleep onset latency (sSOL) under the treatment of HS-10506
sSOL: estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary
Time frame: Baseline, Week 4, Week 12
Change from baseline in subjective sleep efficiency (sSE) under the treatment of HS-10506
sSE: the ratio of subjective total sleep time(sTST) to subjective time in bed, sTST: the total sleep time reported by the participant in sleep diary.
Time frame: Baseline, Week 4, Week 12
Change from baseline in total sleep time (TST) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
TST was defined as the total sleep time in minutes, the total sleep time is the total amount of stages 1, 2, 3 non rapid eye-movement (NREM) and rapid-eye-movement (REM) sleep time, as measured by PSG
Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84
Change from baseline in sleep efficiency (SE) over the last 2 nights of 28 days and 84 days under the treatment of HS-10506
SE was defined as percentage (%) of time spent in bed asleep, calculated as total sleep time (TST) divided by interval from lights off until lights on as measured by PSG multiplied by 100
Time frame: Baseline, Night 27 and Night 28, Night 83 and Night 84
Change from baseline in subjective wake after sleep onset (sWASO) under the treatment of HS-10506
sWASO: estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary
Time frame: Week 4, Week 12
Change from baseline in subjective total sleep time (sTST) under the treatment of HS-10506
sTST: the total sleep time reported by the participant in sleep diary
Time frame: Baseline, Week 4, Week 12
Incidence and severity of adverse events (AE)
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
Incidence and severity of serious adverse events (SAE)
An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above
Time frame: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 4 months
Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)
PWC-20 is a 20-item questionnaire and the score of each item ranges from 0-3 (0=not present, 1=mild, 2=moderate, 3=severe) with higher scores indicating greater severity of withdrawal symptoms
Time frame: The day after the last administration and at least 3 days after discontinuation of the medication
Rebound insomnia by sleep diary during the follow-up period
Rebound insomnia is defined as worsened sleep relative to baseline after study drug treatment was completed, rebound insomnia is assessed using the data collected in sleep diary, including estimated minutes from the time that the participant attempted to sleep until sleep onset as recorded in sleep diary (subjective sleep onset latency, sSOL), estimated minutes of wake at night from initial sleep onset to the time when the participant stopped trying to sleep as recorded in sleep diary (subjective wake after sleep onset, sWASO) and the total sleep time reported by the participant in sleep diary ( subjective total sleep time, sTST)
Time frame: Baseline, Follow-up Period (3-6 days)
No study locations are listed for this record.
Start is estimated for May 2026; primary completion for Jun 2028, 24 months later.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 24 months is above that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HS-10506
Sleep Initiation and Maintenance Disorders →
Jiangsu Hansoh Pharmaceutical Co., Ltd. →